KEY DETAILS
Eloralintide plus tirzepatide produced 23.3% weight loss in a phase 2 trial of adults with type 2 diabetes, beating tirzepatide alone.
Retatrutide, Lilly's triple agonist, showed 21% weight loss in patients with diabetes, adding another contender to the company's pipeline.
Investors weighing Johnson & Johnson against Eli Lilly may want this comparison before deciding which stock to hold in 2026.
A look at Lilly's newest weight loss strategy asks whether this approach could pay off over decades, not just in near term trial results.
New data show orforglipron was noninferior for cardiovascular outcomes in type 2 diabetes, a reassuring safety signal for current users.
Eli Lilly released phase 2 data today showing its experimental amylin analog eloralintide, paired with tirzepatide, produced 23.3% weight loss in adults with type 2 diabetes, outperforming tirzepatide alone. The company also shared fresh results on retatrutide and orforglipron, two other drugs in its pipeline, giving a fuller picture of where Lilly stands heading into 2026. For readers holding or considering Lilly stock, and for anyone comparing it to rivals like Johnson & Johnson, today's releases offer a lot to weigh.
That 23.3% figure puts the eloralintide and tirzepatide combination ahead of tirzepatide given on its own in the same phase 2 study, and it marks the amylin analog's clearest signal yet that pairing it with an existing GLP-1 drug can push weight loss higher than either compound achieves alone. Eloralintide works on a different receptor than tirzepatide, which targets GLP-1 and GIP, so combining the two lets Lilly test whether stacking mechanisms adds meaningful benefit rather than just adding side effects. The company has not said when eloralintide might reach a phase 3 program, but a result like this one usually moves a drug up the priority list.
Retatrutide, Lilly's triple agonist that acts on GLP-1, GIP, and glucagon receptors, delivered 21% weight loss in patients with type 2 diabetes in results also released today. That number sits below the eloralintide combination's 23.3%, but retatrutide is being tested as a single molecule rather than a two-drug pairing, so the comparison is not entirely apples to apples. Lilly now has three distinct weight loss approaches moving through its pipeline at once: tirzepatide on the market, retatrutide in later-stage testing, and eloralintide paired with tirzepatide in earlier trials. That breadth gives the company more than one path forward if any single drug runs into problems in later studies.
All of this pipeline activity matters to anyone deciding between Lilly and Johnson & Johnson stock heading into 2026. Lilly's obesity and diabetes drugs now span multiple mechanisms and stages of development, which gives the company a broader base of potential revenue than a single blockbuster would provide. Johnson & Johnson, by contrast, draws its strength from a different mix of businesses, so the comparison comes down to how much weight an investor wants to place on Lilly's concentrated bet in metabolic disease versus a more diversified portfolio elsewhere. Anyone making that decision should look at today's trial data as one input among several, not the deciding factor on its own.
That question of concentration versus diversification connects directly to a longer-term question analysts are now asking: whether Lilly's current weight loss strategy can keep paying off decades from now, not just in the next round of trial readouts. Early results like the ones out today look strong, but drug development timelines run long, and patent protection, competition from other companies, and shifting insurance coverage can all change the picture well before any of these drugs reach their full commercial life. The honest answer is that nobody knows yet, and anyone holding Lilly stock for the long run should expect the story to keep evolving rather than settling after one strong quarter of data.
On the safety side, new data released today found that orforglipron, Lilly's oral GLP-1 drug, was noninferior for cardiovascular outcomes in people with type 2 diabetes. That result will reassure patients already taking orforglipron, since it suggests the drug does not raise cardiovascular risk compared to the standard of care in this population. Noninferiority is a lower bar than showing a drug actively reduces cardiovascular events, but for a relatively new oral option, clearing that bar is still a meaningful checkpoint. Patients with questions about what this means for their own treatment should raise it with their prescriber rather than drawing conclusions from the trial summary alone.
Today's releases add up to a busy day for Lilly specifically, with new numbers on three different drugs and a safety readout on a fourth. Readers trying to make sense of it all should separate the near-term trial results from the longer-term questions about pricing, competition, and patent timelines that will actually decide how these drugs perform in the market. If you are a patient on one of these drugs, talk to your prescriber about how today's data might apply to your own treatment. If you are an investor, treat this as one data point in a much longer story rather than a signal to act today.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.